Pre-made Pamrevlumab benchmark antibody ( Whole mAb, anti-CTGF/CCN2 therapeutic antibody, Anti-HCS24/IGFBP8/NOV2 Antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Pamrevlumab biosimilar, Whole mAb, Anti-CTGF/CCN2 Antibody: Anti-HCS24/IGFBP8/NOV2 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Pamrevlumab (INN; development code FG-3019) is a humanized monoclonal antibody designed for the treatment of idiopathic pulmonary fibrosis and pancreatic cancer.
| Products Name (INN Index) | Pre-Made Pamrevlumab biosimilar, Whole mAb, Anti-CTGF/CCN2 Antibody: Anti-HCS24/IGFBP8/NOV2 therapeutic antibody |
|---|---|
| INN Name | Pamrevlumab |
| Target | CCN2 |
| Format | Whole mAb |
| Derivation | Human |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-III |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2015 |
| Year Recommended | 2016 |
| Companies | FibroGen |
| Conditions Approved | NA |
| Conditions Active | Duchenne muscular dystrophy,Idiopathic pulmonary fibrosis,Pancreatic cancer |
| Conditions Discontinued | Diabetic cardiomyopathy,Diabetic nephropathies,Diabetic neuropathies,Glioblastoma,Glomerulonephritis,Hepatic fibrosis |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | CTGF |
| Package |
